Drugs Index
Medical Conditions:
- Medical Conditions G
- Medical Conditions I
- Medical Conditions P
- Medical Conditions C
- Medical Conditions N
- Medical Conditions T
- Medical Conditions E
- Medical Conditions D
- Medical Conditions F
- Medical Conditions H
- Medical Conditions M
- Medical Conditions B
- Medical Conditions U
- Medical Conditions O
- Medical Conditions S
- Medical Conditions A
- Medical Conditions R
- Medical Conditions L
- Medical Conditions W
- Medical Conditions V
- Medical Conditions K
- Medical Conditions J
- Medical Conditions X
Drug Classes
- Drug Classes A
- Drug Classes M
- Drug Classes H
- Drug Classes C
- Drug Classes B
- Drug Classes U
- Drug Classes T
- Drug Classes O
- Drug Classes I
- Drug Classes N
- Drug Classes V
- Drug Classes E
- Drug Classes G
- Drug Classes P
- Drug Classes L
- Drug Classes Q
- Drug Classes F
- Drug Classes S
- Drug Classes D
- Drug Classes R
- Drug Classes 5
- Drug Classes K
Drugs Information:
Drugs List
1. Name Of The Medicinal Product
Codeine Linctus BP
2. Qualitative And Quantitative Composition
Codeine Phosphate BP 15mg/5ml dose.
3. Pharmaceutical Form
Linctus.
4. Clinical Particulars
4.1 Therapeutic Indications
Codeine is indicated in adults for relief of the symptoms of dry or irritating coughs.
4.2 Posology And Method Of Administration
Oral.
Recommended doses
Adults: one 5ml spoonful
The elderly: Use with caution, not exceeding the recommended adult dose.
Paediatric population
Codeine should not be used for the treatment of children under the age of 18 years.
Dosage schedule
The dose may be repeated after four hours if required, but not more than 4 doses in any 24 hours.
4.3 Contraindications
Contraindicated:
In cases of liver disease and respiratory depression.
In patients with raised intracranial pressure or head injury.
During an acute asthmatic attack
Hypersensitivity to codeine or to any of the other ingredients.
Concurrent use of monoamine oxidase inhibitors or within 2 weeks discontinuation of their use.
4.4 Special Warnings And Precautions For Use
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Use with caution in patients with large bowel disease, renal impairment or a history of asthma. Prolonged use could aggravate irritable b
1. Name Of The Medicinal Product
COLOMYCIN TABLETS
2. Qualitative And Quantitative Composition
Colistin Sulphate BP 1.5MU per tablet.
3. Pharmaceutical Form
Tablet.
4. Clinical Particulars
4.1 Therapeutic Indications
For the treatment of gastrointestinal infections caused by sensitive Gram negative organisms. Also for bowel preparation.
Colistin sulphate is not absorbed from the gastrointestinal tract and must not, therefore, be used for systemic infections.
4.2 Posology And Method Of Administration
To be taken orally.
Adults (including the elderly) (over 30kg):
1,500,000 to 3,000,000 units every 8 hours.
Children (up to 15kg):
250,000 to 500,000 units every 8 hours.
Children (15-30kg):
750,000 to 1,500,000 units every 8 hours.
A minimum of five days treatment is recommended. Dosage may be increased when clinical or bacteriological response is slow.
For bowel preparation, a 24 hour course at the normal dosage above is given. Treatment should preferably finish 12 hours before surgery.
4.3 Contraindications
Contra-indicated in patients with known sensitivity to colistin and those with myasthenia gravis.
4.4 Special Warnings And Precautions For Use
Colistin is subject to limited and unpredictable absorption from the GI tract in infants under six months. Studies in older children and in adults have demonstrated no systemic absorption of colistin following oral administration.
CANCIDAS 50 mg powder for concentrate for solution for infusion
Caspofungin (as acetate)
Read all of this leaflet carefully before you or your child start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor or your pharmacist.
- This medicine has been prescribed for you or your child. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
- 1. What CANCIDAS is and what it is used for
- 2. Before you take CANCIDAS
- 3. How to take CANCIDAS
- 4. Possible side effects
- 5. How to store CANCIDAS
- 6. Further information
What Cancidas Is And What It Is Used For
CANCIDAS is an antifungal medicine that interferes with the production of a component (glucan polysaccharide) of the fungal cell wall that is necessary if the fungus is to continue living and growing. Fungal cells exposed to CANCIDAS have incomplete or defective cell walls, making them fragile and unable to grow.
CANCIDAS may have been prescribed to treat a serious fungal infection called invasive candidiasis. The infection is caused by fungal (yeast) cells called Candida. These yeast cells are normally found in the digestive tract, and do not cause an infection unless they enter the bloodstream (in which cas
1. Name Of The Medicinal Product
Corsodyl Spray
2. Qualitative And Quantitative Composition
Chlorhexidine Digluconate 0.2% w/v
(equivalent to Chlorhexidine Digluconate Solution Ph Eur 1.0% v/v)
3. Pharmaceutical Form
Oromucosal spray
4. Clinical Particulars
4.1 Therapeutic Indications
For inhibition of the formation of dental plaque.
As an aid in the treatment and prevention of gingivitis and in the maintenance of oral hygiene, particularly in situations where toothbrushing cannot be adequately employed (eg; following oral surgery, in physically or mentally handicapped patients, the terminally ill or immunocompromised patients).
Also for use in a post-peridontal surgery or treatment* regimen to promote gingival healing.
*NB: Use as part of a post-periodontal treatment regimen has only been adequately studied over the short term and following standard root surface instrumentation.
It is useful in the management of aphthous ulceration and oral candidal infections (eg; denture stomatitis and thrush).
4.2 Posology And Method Of Administration
Adults:
Corsodyl spray should be applied as required to the tooth and gingival surfaces, ulcers or other sore areas, using up to a maximum of twelve actuations of the spray (0.14 ml/actuation) twice daily. The spray should be applied once in the morning and once in the evening.
Corsodyl is incompatible with anionic agents which are usually present in conventional dentifrices. These should therefore be used before Corsodyl (rinsing the mouth between applications) or at a different time of day.
For the treatment of gingivitis a course of about one month is advisable although some v
1. Name Of The Medicinal Product
COLOMYCIN INJECTION 1 million or 2 million International Units.
Powder for solution for injection, infusion or inhalation.
2. Qualitative And Quantitative Composition
Each vial contains either 1 million or 2 million International Units Colistimethate Sodium.
For excipients, see 6.1.
3. Pharmaceutical Form
Powder for solution for injection, infusion or inhalation.
|
1 million IU/vial: |
Sterile white powder in a 10ml colourless glass vial with a red 'flip-off' cap. |
|
2 million IU/vial: |
Sterile white powder in a 10ml colourless glass vial with a lilac 'flip-off' cap. |
4. Clinical Particulars
4.1 Therapeutic Indications
Colomycin is indicated in the treatment of the following infections where sensitivity testing suggests that they are caused by susceptible bacteria:
Treatment by inhalation of Pseudomonas aeruginosa lung infection in patients with cystic fibrosis (CF).
Intravenous administration for the treatment of some serious infections caused by Gram-negative bacteria, including those of the lower respiratory tract and urinary tract, when more commonly used systemic antibacterial agents may be contra-indicated or may be ineffective because of bacterial resistance.
4.2 Posology And Method Of Administration
SYSTEMIC TREATMENT
Colomycin can be given as a 50ml intravenous infusion over a period of 30 minutes. Patients with a totally implantable venous access device (TIVAD)
1. Name Of The Medicinal Product
Cisplatin 1 mg/ml Concentrate for Solution for Infusion
2. Qualitative And Quantitative Composition
1 ml of concentrate for solution for infusion contains 1 mg of Cisplatin.
10 ml of concentrate for solution for infusion contains 10 mg of Cisplatin
25 ml of concentrate for solution for infusion contains 25 mg of Cisplatin
50 ml of concentrate for solution for infusion contains 50 mg of Cisplatin
100 ml of concentrate for solution for infusion contains 100 mg of Cisplatin
Each ml of solution contains 3.5 mg of sodium. For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Concentrate for solution for infusion
Clear, colourless to pale yellow solution in an amber glass vial, which is practically free from particles.
4. Clinical Particulars
4.1 Therapeutic Indications
Cisplatin is intended for the treatment of:
• advanced or metastasised testicular cancer
• advanced or metastasised ovarian cancer
• advanced or metastasised bladder carcinoma
• advanced or metastasised squamous cell carcinoma of the head and neck
• advanced or metastasised non-small cell lung carcinoma
• advanced or metastasised small cell lung carcinoma.
• Cisplatin is indicated in the treatment of cervical carcinoma in combination with other chemotherapeutics or with radiotherapy.
• Cisplatin can be used as monotherapy and in combination therapy
4.2 Posology And Method Of Administration
Cisplatin 1 mg/ml concentrate for solution for infusion is to be diluted before administration. For instructions on d
Co-amilozide 5/50mg tablets
(amiloride hydrochloride and hydrochlorothiazide)
Read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them even if their symptoms are the same as yours.
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Index
- 1 What Co-amilozide tablets are and what they are used for
- 2 Before you take
- 3 How to take
- 4 Possible side effects
- 5 How to store
- 6 Further information
What Co-amilozide tablets are and what they are used for
Co-amilozide tablets belong to a group of medicines called diuretics (water tablets). They may be used for:
- high blood pressure
- congestive heart failure
- liver cirrhosis with fluid retention (oedema) and swelling of the abdomen (ascites).
Before you take
Do not take Co-amilozide tablets and tell your doctor if you are:
- allergic
CLOPIDOGREL 75 mg FILM-COATED TABLETS
Clopidogrel
Read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or your pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
- 1. What Clopidogrel Tablets are and what they are used for
- 2. Before you take Clopidogrel Tablets
- 3. How to take Clopidogrel Tablets
- 4. Possible side effects
- 5. How to store Clopidogrel Tablets
- 6. Further information
What Clopidogrel Tablets Are And What They Are Used For
Clopidogrel Tablets belong to a group of medicines called antiplatelet medicinal products. Platelets are very small structures in the blood, smaller than red or white blood cells, which clump together during blood clotting. By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called thrombosis).
Clopidogrel Tablets are taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
You have been prescribed Clopidogrel Tablets to help prevent b
1. Name Of The Medicinal Product
Glycerin and Blackcurrant Soothing Cough Syrup or Glycerin and Blackcurrant Linctus or Benylin Dry Coughs Blackcurrant or CalCough Children's Soothing Syrup or Benylin Children's Blackcurrant Flavour Cough Syrup
2. Qualitative And Quantitative Composition
|
Active Ingredient Glycerin Ph. Eur. Liquid sugar (Equivalent to sucrose B.P. |
Quantity per 5ml 0.75ml 1.93ml 1.7g) |
3. Pharmaceutical Form
Liquid
4. Clinical Particulars
4.1 Therapeutic Indications
For the relief of irritating, tickling dry coughs and sore throats.
4.2 Posology And Method Of Administration
Adults, elderly and children over 5 years: 10ml
Children 1 - 5 years: 5ml
The dose may be repeated three or four times a day.
Children under one year: Not to be given to children under 1 year.
For oral administration.
4.3 Contraindications
Hypersensitivity or intolerance to any of the ingredients.
4.4 Special Warnings And Precautions For Use
Diabetics should take note of the carbohydrate content of this product.
Do not give to children under one year.
Keep all medicines out of the reach of children.
4.5 Interact
1. Name Of The Medicinal Product
Capoten Tablets 25mg and 50mg
2. Qualitative And Quantitative Composition
Each tablet contains 25mg or 50mg captopril.
For excipients, see 6.1
3. Pharmaceutical Form
Capoten Tablets 25mg:
Tablet.
White, slightly mottled, square, biconvex tablet, with “25” embossed on one side and cross scored on the other side.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Capoten Tablets 50mg:
Tablet.
White, slightly mottled oval biconvex tablet, with “50” embossed on one side and scored on the other side
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
4. Clinical Particulars
4.1 Therapeutic Indications
Hypertension: Capoten is indicated for the treatment of hypertension.
Heart Failure: Capoten is indicated for the treatment of chronic heart failure with reduction of systolic ventricular function, in combination with diuretics and, when appropriate, digitalis and beta-blockers.
Myocardial Infarction:
- short-term (4 weeks) treatment: Capoten is indicated in any clinically stable patient within the first 24 hours of an infarction.
- long-term prevention of symptomatic heart failure: Capoten is indicated in clinically stable patients with asymptomatic left ventricular dysfunction (ejection fraction
Type I Diabetic Nephropathy: Capoten is indicated for the treatment of macroproteinuric diabetic nephropathy
1. Name Of The Medicinal Product
Calcichew Forte Chewable Tablets
2. Qualitative And Quantitative Composition
Per tablet: Calcium carbonate 2500mg equivalent to 1g of elemental calcium.
Contains sorbitol, 780mg; isomalt, 124mg; and aspartame, 2mg.
For a full list of excipients see Section 6.1.
3. Pharmaceutical Form
Chewable tablet.
Round, white, uncoated and convex tablets. May have small specks.
4. Clinical Particulars
4.1 Therapeutic Indications
Calcichew Forte Chewable Tablets are to be chewed as a supplemental source of calcium in the correction of dietary deficiencies or when normal requirements are high.
Calcichew Forte Chewable Tablets may be used as an adjunct to conventional therapy in the prevention and treatment of osteoporosis. They may be used as a phosphate binding agent in the management of renal failure in patients on renal dialysis.
4.2 Posology And Method Of Administration
Oral.
Adults and elderly:
|
Adjunct to osteoporosis therapy |
One tablet to be chewed daily. |
|
Dietary deficiency |
One tablet to be chewed daily. |
|
Osteomalacia |
1-3 tablets da |
1. Name Of The Medicinal Product
Copaxone 20 mg/ml Solution for Injection, Pre-filled Syringe.
2. Qualitative And Quantitative Composition
1 ml of solution for injection contains 20 mg glatiramer acetate*, equivalent to 18 mg of glatiramer base per pre-filled syringe.
* Glatiramer acetate is the acetate salt of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine and L-lysine, in molar fraction ranges of 0.129-0.153, 0.392-0.462, 0.086-0.100 and 0.300-0.374, respectively. The average molecular weight of glatiramer acetate is in the range of 5,000-9,000 daltons.
For full list of excipients, see section 6.1.
3. Pharmaceutical Form
Solution for Injection, Pre-filled Syringe.
Clear solution free of visible particles.
4. Clinical Particulars
4.1 Therapeutic Indications
Copaxone is indicated for the treatment of patients who have experienced a well-defined first clinical episode and are determined to be at high risk of developing clinically definite multiple sclerosis (CDMS) (see Section 5.1).
Copaxone is indicated for the reduction in frequency of relapses in ambulatory patients (i.e. who can walk unaided) with relapsing-remitting multiple sclerosis (MS). In clinical trials this was characterised by at least two attacks of neurological dysfunction over the preceding two-year period (see Section 5.1).
Copaxone is not indicated in primary or secondary progressive MS.
4.2 Posology And Method Of Administration
The recommended dosage in adults is 20 mg of glatiramer acetate (one pre-filled syringe), administered as a subcutaneous injection once daily.
At the present time, it is not known for how lon
1. Name Of The Medicinal Product
Codipar 15mg/500mg Effervescent Tablets
2. Qualitative And Quantitative Composition
Each tablet contains Codeine Phosphate hemihydrate 15mg.and Paracetamol 500mg,
Excipients: Each tablet also contains 389mg of sorbitol and 379 mg of sodium.
For a full list of excipients, see 6.1.
3. Pharmaceutical Form
Effervescent Tablet
Bevelled, flat, round, white tablet
4. Clinical Particulars
4.1 Therapeutic Indications
For the relief of mild to severe acute pain
4.2 Posology And Method Of Administration
Method of administration: Oral
The tablets should be placed in a glass of water and allowed to be dissolved completely. The resulting solution should be drunk immediately.
Adults: The usual dose is two tablets every four hours as required. The total daily dose should not exceed 4 g paracetamol (8 tablets in a day).
Elderly; As for adults, however a reduced dose may be required (see section 4.4)
Paediatric population: Not recommended in children below the age of 18 years (see section 5.1).
4.3 Contraindications
Hypersensitivity to either paracetamol or codeine, or any of the excipients of Codipar tablets.
Conditions where morphine and opioids are contraindicated e.g., acute asthma, respiratory depression, acute alcoholism, head injuries, raised intra-cranial pressure and following biliary tract surgery; monoamine oxidase inhibitor therapy, concurrent or within 14 days.
Codipar is also contraindicated in severe liv
1. Name Of The Medicinal Product
CUROSURF® 120mg / vial Endotracheopulmonary Instillation Suspension
CUROSURF® 240mg / vial Endotracheopulmonary Instillation Suspension
2. Qualitative And Quantitative Composition
One 1.5 ml vial contains 120mg of phospholipid fraction from porcine lung (poractant alfa).
One 3.0ml vial contains 240mg of phospholipid fraction from porcine lung (poractant alfa).
Composition per ml of suspension: phospholipid fraction from porcine lung 80mg/ml, equivalent to about 74mg/ml of total phospholipids and 0.9mg/ml of low molecular weight hydrophobic proteins.
CUROSURF is a natural surfactant, prepared from porcine lungs, containing almost exclusively polar lipids, in particular phosphatidylcholine (about 70% of the total phospholipid content), and about 1% of specific low molecular weight hydrophobic proteins SP-B and SP-C.
For excipients, see 6.1
3. Pharmaceutical Form
Endotracheopulmonary instillation suspension
A white to yellow sterile suspension for endotracheopulmonary instillation in single dose vials.
4. Clinical Particulars
4.1 Therapeutic Indications
For the treatment of Respiratory Distress Syndrome (RDS) or hyaline membrane disease in newborn babies with birth weight over 700g.
Prophylactic use in premature infants between 24 and 31 weeks estimated gestational age at risk from RDS or with evidence of surfactant deficiency.
4.2 Posology And Method Of Administration
4.2.1 Posology
4.2.1.1 Rescue treatment
The recommended starting dose is 100-200mg/kg (1.25-2.5ml/kg), administered in a single
1. Name Of The Medicinal Product
Carbimazole 20mg tablets
2. Qualitative And Quantitative Composition
Each tablet contains 20mg of carbimazole
For a full list of excipients see section 6.1
3. Pharmaceutical Form
Tablet
Pale pink, uncoated, round, biconvex tablets marked with LINK C20 on one side and a scoreline on the reverse.
4. Clinical Particulars
4.1 Therapeutic Indications
Carbimazole is an anti-thyroid agent. It is indicated in all conditions where reduction of thyroid function is required.
Such conditions are:
1. Hyperthyroidism.
2. Preparation for thyroidectomy in hyperthyroidism.
3. Therapy prior to and post radio-iodine treatment.
4.2 Posology And Method Of Administration
Carbimazole should only be administered if hyperthyroidism has been confirmed by laboratory tests.
Adult:
The initial dose is in the range 20mg to 60mg, taken as two to three divided doses. The dose should be titrated against thyroid function until the patient is euthyroid in order to reduce the risk of over-treatment and resultant hypothyroidism.
Subsequent therapy may then be administered in one of two ways.
Maintenance regimen: Final dosage is usually in the range 5mg to 15mg per day, which may be taken as a single daily dose. Therapy should be continued for at least six months and up to eighteen months. Serial thyroid function monitoring is recommended, together with appropriate dosage modification in order to maintain a euthyroid state.
Blocking-replacement regimen: dosage is maintained at the initial level, i.e. 20mg to 60mg per day,
1. Name Of The Medicinal Product
Chloromycetin Ophthalmic Ointment
2. Qualitative And Quantitative Composition
Each 1 gram of ointment contains 10mg of chloramphenicol Ph Eur.
3. Pharmaceutical Form
Eye ointment.
4. Clinical Particulars
4.1 Therapeutic Indications
Chloramphenicol is a broad spectrum antibiotic for the treatment of bacterial conjunctivitis caused by chloramphenicol susceptible organisms including; Escherichia coli, Haemophilus influenzae, Staphylococcus aureus, Streptococcus haemolyticus, Morax-Axenfeld, Klebsiella/Enterobacter species and others.
4.2 Posology And Method Of Administration
Topical administration to the eye only.
Adults, children and infants:
The recommended dosage for adults, children and infants of all age groups is a small amount of the ointment to be applied to the affected eye every 3 hours or more frequently if required. Treatment should be continued for at least 48 hours after the eye appears normal.
Elderly (over 65 years):
As for adults. Chloramphenicol has been used successfully at normal dosages in elderly patients. The pattern and incidence of adverse effects does not appear to differ from younger adults.
4.3 Contraindications
Chloromycetin Ophthalmic Ointment should not be administered to patients hypersensitive to chloramphemcol or any other component of the preparation.
4.4 Special Warnings And Precautions For Use
Chloramphenicol is absorbed systemically from the eye and toxicity has been reported following chronic exposure. Bone marrow hypoplasia,
1. Name Of The Medicinal Product
CellCept 1 g/5 ml powder for oral suspension.
2. Qualitative And Quantitative Composition
Each bottle contains 35 g mycophenolate mofetil in 110 g powder for oral suspension. 5 ml of the reconstituted suspension contains 1 g of mycophenolate mofetil.
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Powder for oral suspension.
4. Clinical Particulars
4.1 Therapeutic Indications
CellCept 1 g/5 ml powder for oral suspension is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
4.2 Posology And Method Of Administration
Treatment with CellCept should be initiated and maintained by appropriately qualified transplant specialists.
Use in renal transplant:
Adults: oral CellCept 1 g/5 ml powder for oral suspension should be initiated within 72 hours following transplantation. The recommended dose in renal transplant patients is 1 g administered twice daily (2 g daily dose), i.e. 5 ml oral suspension twice daily.
Children and adolescents (aged 2 to 18 years): the recommended dose of CellCept 1 g/5 ml powder for oral suspension is 600 mg/m2 administered twice daily (up to a maximum of 2 g/10 ml oral suspension daily). As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors includin
Read all of this leaflet carefully before you start taking this medicine.
Keep this leaflet; you may want to read it again.
If you have further questions, please ask your doctor or pharmacist.
This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours.
Calcium Folinate 15 mg Tablets
- The active ingredient is calcium folinate equivalent to folinic acid 15 mg.
- The other ingredients are microcrystalline cellulose, magnesium stearate and lactose.
The Marketing Authorisation Holder is
The manufacturer is Orion Corporation.
What Calcium Folinate Tablets are and what they are used for
Calcium Folinate is a vitamin from the B group.
This medicinal product is presented in a bottle. Each bottle contains 10 tablets.
Calcium Folinate is used:
- to reduce the harmful effects and treat overdose of certain types of anti-cancer medicines e.g. methotrexate
- to treat a
1. Name Of The Medicinal Product
Cerazette® 75 microgram film-coated tablet.
2. Qualitative And Quantitative Composition
Each tablet contains 75 microgram desogestrel.
Excipient: lactose <65mg.
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Film-coated tablet.
The tablet is white, round, biconvex and 5 mm in diameter. On one side it is coded KV above 2 and on the reverse side Organon *.
4. Clinical Particulars
4.1 Therapeutic Indications
Contraception.
4.2 Posology And Method Of Administration
4.2.1 How to take Cerazette
Tablets must be taken every day at about the same time so that the interval between two tablets always is 24 hours. The first tablet should be taken on the first day of menstrual bleeding. Thereafter one tablet each day is to be taken continuously, without taking any notice on possible bleeding. A new blister is started directly the day after the previous one.
4.2.2 How to start Cerazette
No preceding hormonal contraceptive use [in the past month]
Tablet-taking has to start on day 1 of the woman's natural cycle (day 1 is the first day of her menstrual bleeding). Starting on days 2-5 is allowed, but during the first cycle a barrier method is recommended for the first 7 days of tablet-taking.
Following first-trimester abortion
After first-trimester abortion it is recommended to start immediately. In that case there is no need to use an additional method of contraception.
Following delive
1. Name Of The Medicinal Product
Co-dydramol Tablets
2. Qualitative And Quantitative Composition
|
Dihydrocodeine Tartrate BP |
10.0 |
mg |
|
Paracetamol BP |
500.0 |
mg |
3. Pharmaceutical Form
Tablet.
4. Clinical Particulars
4.1 Therapeutic Indications
a) As an analgesic.
b) As an antitussive.
4.2 Posology And Method Of Administration
Codydramol tablets should be taken, if possible, during or after meals.
As an analgesic:
Adults and children over 12 years: 1 tablet every four hours. This may if necessary be increased to 2 tablets four times daily.
As an antitussive:
Adults and children over 12 years: 1 tablet every four hours.
Not recommended for children under 12 years.
Dosage should be reduced in the elderly.
Do not exceed 8 tablets in 24 hours.
For oral administration.
4.3 Contraindications
Respiratory depression, obstructive airway disease, allergic disorders, during an attack of asthma.
4.4 Special Warnings And Precautions For Use
Use wi